^
    BIOMARKER:

    FLT3 mutation

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2




    Show legend

    Include preclinical:
    Acute Myelogenous Leukemia
    Myelodysplastic Syndrome
    Leukemia
    Non Small Cell Lung Cancer
    Chronic Myeloid Leukemia
    gemtuzumab ozogamicin
    HIA + azacitidine
    HAG + azacitidine
    azacitidine
    HDA + azacitidine
    venetoclax + gilteritinib
    HM43239
    venetoclax + azacitidine
    CA-4948
    midostaurin
    quizartinib
    ARO-002
    cytarabine + cladribine
    decitabine + clofarabine
    decitabine + cladribine
    midostaurin + cytarabine/daunorubicin liposomal formulation
    venetoclax
    FLT3 inhibitor
    quizartinib + RAIN-32
    sunitinib
    Hypomethylating agent + venetoclax
    CEP-701
    sorafenib
    FLT3 inhibitor + gilteritinib
    ORY-1001
    GS-9876
    GS-9973
    STI-8591
    cytarabine + midostaurin
    venetoclax + midostaurin
    venetoclax + sorafenib
    nintedanib
    cytarabine + clofarabine
    midostaurin + gemtuzumab ozogamicin
    gilteritinib
    cytarabine + bortezomib + omacetaxine mepesuccinate
    PHI-101
    XY0206
    olutasidenib
    cytarabine/daunorubicin liposomal formulation
    MEK inhibitor + FLT3 inhibitor
    gilteritinib + RMC-7977
    TP-0184
    sorafenib + LY3009120
    5-fluorouracil
    quizartinib + IACS-010759
    AG-1296
    venetoclax + TP-0184
    SU5614
    ASP7487 + NT-157
    FLT3 inhibitor + venetoclax + decitabine
    venetoclax + olaparib
    OTS167
    ivosidenib
    cytarabine
    gilteritinib + ERAS-601
    quizartinib + SGN-CD123A
    lintuzumab-Ac225
    gilteritinib + RVU120